3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Lung Neoplasms
7
Pain, Postoperative
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Smoking Cessation
1
Respiration Disorders
1
Psychological Well-Being
1
Pleural Diseases
1
Motor Activity
1
Lung Cancer Prevention
1
Esophageal Neoplasms
1
Chronic Pain
1
Agnosia
1
Acute Pain
1
Interventions
pembrolizumab
24
Magnetic Resonance Spectroscopy
10
Carboplatin
8
Nivolumab
7
Docetaxel
7
Paclitaxel
6
Gemcitabine
6
Trastuzumab
5
Taxes
5
Injections
5
Fluorouracil
5
Fluorodeoxyglucose F18
5
Drug Therapy
5
Cyclophosphamide
5
Cisplatin
5
fludarabine
4
X-Rays
4
Specimen Handling
4
Radiotherapy
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Leucovorin
4
durvalumab
3
atezolizumab
3
Surveys and Questionnaires
3
Standard of Care
3
Irinotecan
3
Immunohistochemistry
3
Gene Expression Profiling
3
Early Intervention, Educational
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Tea
×
Thoracic
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled